A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients - PACIFIC-5

Study identifier:D933YC00001

ClinicalTrials.gov identifier:NCT03706690

EudraCT identifier:2018-002294-22

CTIS identifier:N/A

Recruitment Complete

Official Title

A Phase III, Randomised,Double-Blind,Placebo-Controlled,Study of Durvalumab as Consolidation Therapy in Patients with Locally Advanced,Unresectable NSCLC, Who Have Not Progressed following Definitive, Platinum-Based Chemoradiation Therapy

Medical condition

Carcinoma, Non-Small-Cell Lung

Phase

Phase 3

Healthy volunteers

No

Study drug

Durvalumab

Sex

All

Actual Enrollment

407

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 27 Nov 2018
Primary Completion Date: 23 Jun 2024
Estimated Study Completion Date: 16 Mar 2027

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Aug 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria